Interest of Famotidine in Children With Sickle Cell Disease
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether oral famotidine, a histamine type 2
receptor antagonist already widely used with very few side effects in other indications in
children, is effective in reducing endothelial expression of P-selectin in children with
sickle cell disease (SCD).
This pilot study will constitute the essential prerequisite for a randomized clinical trial
comparing the efficacy of famotidine with that of placebo in the prevention of vaso-occlusive
crises in SCD patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborator:
INSERM U 1163 - Laboratory of molecular mechanisms of hematologic disorders and therapeutic implications, Paris